Page 82 - GPD-3-2

Gene & Protein in Disease Opportunities and challenges of HIF-1 in cancer

80. Yeom CJ, Zeng L, Goto Y, et al. LY6E: A conductor of HIF-1-targeted combination cancer therapy. Theranostics.
malignant tumor growth through modulation of the PTEN/ 2020;10(7):2918-2929.
PI3K/Akt/HIF-1 axis. Oncotarget. 2016;7(40):65837-65848.
doi: 10.7150/thno.41077
doi: 10.18632/oncotarget.11670
92. Peng J, Zhang H, Yuan Y, et al. Docetaxel suppressed cell
81. Koh MY, Powis G. HAF: The new player in oxygen-independent proliferation through Smad3/HIF-1α-mediated glycolysis
HIF-1α degradation. Cell Cycle. 2009;8(9):1359-1366. in prostate cancer cells. Cell Commun Signal. 2022;20(1):194.
doi: 10.4161/cc.8.9.8303 doi: 10.1186/s12964-022-00950-z
82. Guan Z, Ding C, Du Y, et al. HAF drives the switch of 93. Oh ET, Kim CW, Kim SJ, Lee JS, Hong SS, Park HJ. Docetaxel
HIF-1α to HIF-2α by activating the NF-ΚB pathway, induced-JNK2/PHD1 signaling pathway increases
leading to malignant behavior of T24 bladder cancer cells. degradation of HIF-1α and causes cancer cell death under
Int J Oncol. 2013;44(2):393-402. hypoxia. Sci Rep. 2016;6(1):27382.
doi: 10.3892/ijo.2013.2210 doi: 10.1038/srep27382
83. Koh MY, Lemos R, Liu X, Powis G. The hypoxia- 94. Dingemans AMC, Groen HJM, Herder GJM, et al.
associated factor switches cells from HIF-1 - to Randomized phase II study comparing paclitaxel-
HIF-2 -dependent signaling promoting stem cell carboplatin-bevacizumab with or without nitroglycerin
characteristics, aggressive tumor growth and invasion. patches in patients with stage IV nonsquamous nonsmall-
Cancer Res. 2011;71(11):4015-4027.
cell lung cancer: NVALT12 (NCT01171170). Ann Oncol.
doi: 10.1158/0008-5472.can-10-4142 2015;26(11):2286-2293.
84. Shurin MR, Umansky V. Cross-talk between HIF and PD-1/ doi: 10.1093/annonc/mdv370
PD-L1 pathways in carcinogenesis and therapy. J Clin Invest.
2022;132(9):e159473. 95. Yasuda H, Nakayama K, Watanabe M, et al. Nitroglycerin
treatment may enhance chemosensitivity to docetaxel and
doi: 10.1172/jci159473 carboplatin in patients with lung adenocarcinoma. Clin
85. Samec M, Liskova A, Koklesova L, et al. Flavonoids targeting Cancer Res. 2006;12(22):6748-6757.
HIF-1: Implications on cancer metabolism. Cancers (Basel). doi: 10.1158/1078-0432.ccr-06-1124
2021;13(1):130.
96. Arrieta O, Blake M, de la Mata-Moya MD, et al. Phase II
doi: 10.3390/cancers13010130 study. Concurrent chemotherapy and radiotherapy with
86. Onnis B, Rapisarda A, Melillo G. Development of nitroglycerin in locally advanced non-small cell lung cancer.
HIF-1 inhibitors for cancer therapy. J Cell Mol Med. Radiother Oncol. 2014;111(2):311-315.
2009;13(9a):2780-2786. doi: 10.1016/j.radonc.2014.01.021
doi: 10.1111/j.1582-4934.2009.00876.x 97. Li H, Sun X, Li J, et al. Hypoxia induces docetaxel resistance
87. Ziello JE, Jovin IS, Huang Y. Hypoxia-inducible factor in triple-negative breast cancer via the HIF-1α/MiR-494/
(HIF)-1 regulatory pathway and its potential for therapeutic survivin signaling pathway. Neoplasia. 2022;32:100821.
intervention in malignancy and ischemia. Yale J Biol Med. doi: 10.1016/j.neo.2022.100821
2007;80(2):51-60.
98. Doublier S, Belisario DC, Polimeni M, et al. HIF-1 activation
88. Afsar CU, Uysal P. HIF-1α levels in patients receiving
chemoradiotherapy for locally advanced non-small cell lung induces doxorubicin resistance in MCF7 3-D spheroids via
carcinoma. Rev Assoc Méd Bras (1992). 2019;65(10):1295-1299. P-glycoprotein expression: A potential model of the chemo-
resistance of invasive micropapillary carcinoma of the
doi: 10.1590/1806-9282.65.10.1295 breast. BMC Cancer. 2012;12(1):4.
89. Warfel NA, El-Deiry WS. HIF-1 signaling in drug resistance doi: 10.1186/1471-2407-12-4
to chemotherapy. Curr Med Chem. 2014;21(26):3021-3028.
99. Fourie C, du Plessis M, Mills J, Engelbrecht AM. The effect of
doi: 10.2174/0929867321666140414101056 HIF-1α inhibition in breast cancer cells prior to doxorubicin
90. Jin X, Gong L, Peng Y, Li L, Liu G. Enhancer-bound Nrf2 treatment under conditions of normoxia and hypoxia. Exp
licenses HIF-1α transcription under hypoxia to promote Cell Res. 2022;419(2):113334.
cisplatin resistance in hepatocellular carcinoma cells. Aging doi: 10.1016/j.yexcr.2022.113334
(Albany NY). 2020;13(1):364.
100. Yang Y, Chen DZ, Rey S, Liu JO, Semenza GL. Daily
doi: 10.18632/aging.202137 administration of low-dose daunorubicin or doxorubicin
91. Zhang X, He C, Liu X, et al. One-pot synthesis of a inhibits hypoxia-inducible factor 1 and tumor
microporous organosilica-coated cisplatin nanoplatform for vascularization. bioRxiv. 2022:492526.

Volume 3 Issue 2 (2024) 15 doi: 10.36922/gpd.3431